Analysts Offer Predictions for DENTSPLY SIRONA Q3 Earnings

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Stock analysts at Zacks Research decreased their Q3 2024 earnings per share (EPS) estimates for shares of DENTSPLY SIRONA in a note issued to investors on Monday, October 21st. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings of $0.47 per share for the quarter, down from their prior forecast of $0.48. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.98 per share. Zacks Research also issued estimates for DENTSPLY SIRONA's FY2024 earnings at $1.96 EPS, FY2025 earnings at $2.26 EPS, Q3 2026 earnings at $0.61 EPS and FY2026 earnings at $2.50 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported $0.49 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.01). DENTSPLY SIRONA had a negative net margin of 4.75% and a positive return on equity of 11.86%. The business had revenue of $984.00 million for the quarter, compared to the consensus estimate of $993.61 million. During the same period in the prior year, the business earned $0.51 earnings per share. DENTSPLY SIRONA's revenue was down 4.3% compared to the same quarter last year.

XRAY has been the subject of a number of other research reports. Needham & Company LLC restated a "buy" rating and set a $34.00 target price on shares of DENTSPLY SIRONA in a research report on Tuesday, August 20th. Evercore ISI dropped their price objective on shares of DENTSPLY SIRONA from $29.00 to $27.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Robert W. Baird reduced their target price on DENTSPLY SIRONA from $33.00 to $31.00 and set a "neutral" rating on the stock in a report on Monday, July 22nd. Stifel Nicolaus dropped their price target on DENTSPLY SIRONA from $30.00 to $28.00 and set a "hold" rating for the company in a research note on Thursday, July 18th. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of DENTSPLY SIRONA in a research note on Friday, September 20th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA has an average rating of "Moderate Buy" and a consensus price target of $33.22.

DENTSPLY SIRONA Price Performance

XRAY stock traded down $0.15 during midday trading on Tuesday, hitting $24.28. The company's stock had a trading volume of 1,202,206 shares, compared to its average volume of 2,974,432. The firm has a market capitalization of $4.92 billion, a price-to-earnings ratio of -28.23, a price-to-earnings-growth ratio of 1.19 and a beta of 1.00. The company has a quick ratio of 0.87, a current ratio of 1.33 and a debt-to-equity ratio of 0.57. DENTSPLY SIRONA has a 12 month low of $23.58 and a 12 month high of $37.60. The company has a 50 day moving average of $25.30 and a two-hundred day moving average of $26.61.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 11th. Stockholders of record on Friday, September 27th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 2.64%. The ex-dividend date of this dividend was Friday, September 27th. DENTSPLY SIRONA's dividend payout ratio is currently -74.42%.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently made changes to their positions in XRAY. Raymond James Trust N.A. boosted its holdings in DENTSPLY SIRONA by 4.9% during the 2nd quarter. Raymond James Trust N.A. now owns 9,658 shares of the medical instruments supplier's stock valued at $241,000 after acquiring an additional 453 shares during the period. LRI Investments LLC boosted its stake in shares of DENTSPLY SIRONA by 82.7% during the second quarter. LRI Investments LLC now owns 1,246 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 564 shares during the period. Diversified Trust Co grew its holdings in shares of DENTSPLY SIRONA by 3.0% in the second quarter. Diversified Trust Co now owns 19,637 shares of the medical instruments supplier's stock worth $489,000 after purchasing an additional 566 shares during the last quarter. Epoch Investment Partners Inc. increased its stake in DENTSPLY SIRONA by 2.2% in the 2nd quarter. Epoch Investment Partners Inc. now owns 30,169 shares of the medical instruments supplier's stock worth $752,000 after buying an additional 647 shares during the period. Finally, Envestnet Portfolio Solutions Inc. lifted its holdings in DENTSPLY SIRONA by 6.6% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 10,748 shares of the medical instruments supplier's stock valued at $357,000 after buying an additional 662 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company's stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.